Phase 1 RCT of oral SOR102 (bispecific TNF/IL-23 inhibitor) vs placebo in 64 healthy participants and patients with ulcerative colitis: adverse events were mostly mild to moderate; two on twice-daily SOR102 had worsening colitis. Early efficacy signals in 22 patients.
RCTn = 64
Jairath et al. Safety and pharmacokinetics of SOR102, an oral bispecific inhibitor of TNF and interleukin-23 in healthy participants and patients with ulcerative colitis: a first-in-human, double-blind, randomised, placebo-controlled, phase 1 trial